CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation

In 2022, 20 million women globally were living with HIV, yet they remain underrepresented in clinical trials, including those for antiretroviral treatments (ART). This study assesses the safety and efficacy of the long-acting cabotegravir-rilpivirine (CAB-RPV) regimen in a cohort of 54 women living...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Serena Spampinato, Emmanuele Venanzi Rullo, Giuseppe Nicolò Conti, Andrea De Vito, Andrea Marino, Teresa Cirelli, Viviana Coco, Alessia Mirabile, Rossella Fontana del Vecchio, Antonina Franco, Arturo Montineri, Chiara Frasca, Chiara Gullotta, Michele Salvatore Paternò Raddusa, Ylenia Russotto, Aakash Fugooah, Sarah Pulvirenti, Sonia Sofia, Grazia Pantò, Claudia Calì, Roberto Bruno, Eugenia Pistarà, Nunziatina Villari, Carmelo Iacobello, Bruno Cacopardo, Benedetto Maurizio Celesia, Giovanni F. Pellicanò, Francesco P. Antonucci, Giordano Madeddu, Sergio Lo Caputo, Giuseppe Nunnari
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2025-06-01
Serier:	Pathogens
Fag:	HIV long acting Cabotegravir-Rilpivirine CD4/CD8 ratio
Online adgang:	https://www.mdpi.com/2076-0817/14/7/633
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!